Edit Seeking Alpha
07 Sep 2011
Like most of the products that have been partnered in this space recently, Evotec’s compound is very early stage, having only completed phase I studies (see table below) ... Free radicals ... Worth pursuing ... Indeed Roche had developed the most advanced MAO-B inhibitor so far, lazabemide, which generated decent efficacy data in a phase III trial but was ditched by the Swiss group back in 1999 due to concerns over renal safety ... ....(size: 6.4Kb)







×